X4 Pharmaceuticals Inc.

NASDAQ: XFOR · Real-Time Price · USD
3.95
0.14 (3.67%)
At close: Jun 03, 2025, 3:59 PM
3.98
0.88%
Pre-market: Jun 04, 2025, 08:00 AM EDT

X4 Pharmaceuticals Statistics

Share Statistics

X4 Pharmaceuticals has 5.79M shares outstanding. The number of shares has increased by 0.49% in one year.

Shares Outstanding 5.79M
Shares Change (YoY) 0.49%
Shares Change (QoQ) 0.82%
Owned by Institutions (%) 49.7%
Shares Floating n/a
Failed to Deliver (FTD) Shares 318
FTD / Avg. Volume 0.27%

Short Selling Information

The latest short interest is 312.3K, so 5.4% of the outstanding shares have been sold short.

Short Interest 312.3K
Short % of Shares Out 5.4%
Short % of Float 5.47%
Short Ratio (days to cover) 1.74

Valuation Ratios

The PE ratio is -118.17 and the forward PE ratio is -0.44. X4 Pharmaceuticals's PEG ratio is 1.75.

PE Ratio -118.17
Forward PE -0.44
PS Ratio 1730.67
Forward PS 0.1
PB Ratio 199.8
P/FCF Ratio -33.72
PEG Ratio 1.75
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 3.53.

Current Ratio 3.41
Quick Ratio 3.33
Debt / Equity 3.53
Debt / EBITDA -2.83
Debt / FCF -0.6
Interest Coverage -4.15

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $17,881.12
Profits Per Employee $-261,888.11
Employee Count 143
Asset Turnover 0.02
Inventory Turnover 0.28

Taxes

Income Tax 310K
Effective Tax Rate -0.83%

Stock Price Statistics

The stock price has increased by -87.81% in the last 52 weeks. The beta is 0.73, so X4 Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.73
52-Week Price Change -87.81%
50-Day Moving Average 4.98
200-Day Moving Average 13.57
Relative Strength Index (RSI) 50.47
Average Volume (20 Days) 119,126

Income Statement

In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -0.19.

Revenue 2.56M
Gross Profit 1.76M
Operating Income -36.4M
Net Income -37.45M
EBITDA -27.58M
EBIT -28.37M
Earnings Per Share (EPS) -0.19
Full Income Statement

Balance Sheet

The company has 55.7M in cash and 78.09M in debt, giving a net cash position of -22.39M.

Cash & Cash Equivalents 55.7M
Total Debt 78.09M
Net Cash -22.39M
Retained Earnings -515.36M
Total Assets 130.01M
Working Capital 69.81M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -130.9M and capital expenditures -326K, giving a free cash flow of -131.23M.

Operating Cash Flow -130.9M
Capital Expenditures -326K
Free Cash Flow -131.23M
FCF Per Share -0.65
Full Cash Flow Statement

Margins

Gross margin is 68.83%, with operating and profit margins of -1423.58% and -1464.61%.

Gross Margin 68.83%
Operating Margin -1423.58%
Pretax Margin -1452.48%
Profit Margin -1464.61%
EBITDA Margin -1078.45%
EBIT Margin -1423.58%
FCF Margin -5132.07%

Dividends & Yields

XFOR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for XFOR is $90, which is 2178.5% higher than the current price. The consensus rating is "Buy".

Price Target $90
Price Target Difference 2178.5%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Stock Splits

The last stock split was on Apr 28, 2025. It was a backward split with a ratio of 1:30.

Last Split Date Apr 28, 2025
Split Type backward
Split Ratio 1:30

Scores

Altman Z-Score -1.6
Piotroski F-Score 5